Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Cancer Immunol Res. 2017 Nov 6;5(12):1152–1161. doi: 10.1158/2326-6066.CIR-17-0189

Fig. 1. Cytotoxicity of c-Met-CAR T cells.

Fig. 1

Chromium release cytolytic activity assays of mRNA CAR T cells in two breast cancer cell lines, BT20 and TB129. Each assay was performed in duplicates and repeated in at least three independent experiments. A) Upper panel, BT20 tumor cell lysis induced by CAR T directed against c-Met (cMet.BBz, solid triangles), mesothelin (SS1.BBz, solid squares) or CD19 (CD19.BBz, solid circles) at various effector T cell:tumor cell (E:T) ratios. mRNA c-Met-CAR T cells were more effective than mRNA meso-CAR T cells in inducing CAR T cell directed tumor cell lysis. Lower panel, histograms of flow cytometry analyses of c-Met and mesothelin expression on BT20 cells as stained by antibodies against c-Met and mesothelin. B) Upper panel, TB129 tumor cell lysis induced by CAR T directed against c-Met (cMet.BBz, solid triangles), mesothelin (SS1.BBz, solid squares) or CD19 (CD19.BBz, solid circles) at various E:T ratios. mRNA c-Met-CAR T cells cytolytic activity was similar to that of mRNA meso-CAR T cells in inducing CAR T directed tumor cell lysis. Lower panel, histograms of flow cytometry analyses of TB129 cells as stained by antibodies against c-Met and mesothelin.